1






                                                     EXHIBIT 99.2

                                            
FOR IMMEDIATE RELEASE    MEDIA CONTACTS:
February 14, 1996        Cheryl Greenhouse        Sheila Shuster
                         Genzyme Corp.            Genetrix
                         617-252-7570             602-945-4363


                     GENZYME TO ACQUIRE GENETRIX FOR STOCK

CAMBRIDGE, Mass. -- Genzyme Corp.'s General Division (Nasdaq: GENZ) announced
today that it has signed a definitive agreement to acquire Genetrix Inc., a
privately held genetic testing laboratory based in Phoenix, and merge it with
Genzyme's Integrated Genetics diagnostic services business.

     Under the terms of the agreement, Genetrix shareholders will receive
shares of Genzyme General Division common stock in a tax-free exchange for
their Genetrix common and preferred shares.  The number of shares of Genzyme
General Division common stock to be issued will be fixed at approximately
545,000 provided the average closing price of the stock for the 10 trading days
ending two days prior to completing the transaction is not less than $67.28.
The transaction is expected to be completed in March.

     "The combination of these genetic testing businesses will create operating
synergies that will result in significant cost savings," said Henri A. Termeer,
Genzyme's chairman and chief executive officer.  "As a result of this
acquisition, we will be able to offer a broader range of services over a larger
geographic area, resulting in better service for our customers."

     Both Integrated Genetics and Genetrix have a strong clinical presence and
a commitment to excellent customer service.  Each entity also brings specific
strengths to the combined organization.  Integrated Genetics has strong
capabilities in research and development and prenatal and molecular
diagnostics.  Genetrix has a strong presence in the cancer market and
innovative managed care programs.

     "The merger will create value for our patients, our clients, our
shareholders, and our employees," said Paul R. Sohmer, M.D., Genetrix's
president and chief executive officer.  "Together we will be a unique and
integral player in the delivery of quality and cost-effective health care."

     The transaction will be accounted for as a pooling of interests.  Genzyme
expects that the additional income brought about by the transaction will exceed
the effects of the newly issued shares.  The combined annual genetic testing
revenue will be approximately $75 million.

     One of the world's top five biotechnology companies, Genzyme focuses on
developing innovative products and services for major unmet medical needs.  The
company's General Division markets Ceredase [REGISTERED TRADEMARK] and Cerezyme
[REGISTERED TRADEMARK] replacement enzymes for the treatment of Gaucher 
disease.  It also develops and markets surgical and diagnostic products, 
genetic diagnostic services and bulk pharmaceuticals.

                                    * * *

Genzyme's releases are on the World Wide Web at http://www.prnewswire.com and
PR Newswire's fax- on-demand service at 1-800-758-5804, ext. 104284.